Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s13577-020-00407-w http://scihub22266oqcxt.onion/10.1007/s13577-020-00407-w 32780299!7418088!32780299     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hum+Cell 2020 ; 33 (4): 907-918 Nephropedia Template TP {{tp|p=32780299|t=2020. Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective |pdf=|usr=}}{{32780299}} gab.com Text Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective JO: Hum Cell http://www.kidney.de/pget.php?&tw=1&pmid=32780299 #FOAvip Acute respiratory distress syndrome (ARDS) is the main cause for the COVID-19 infection-related morbidity and mortality. Recent clinical evidences suggest increased level of cytokines and chemokines targeting lung tissue as a prominent etiological factor. The immunomodulatory effect of mesenchymal stem cells (MSCs) as the alternative therapy for the treatment of inflammatory and autoimmune diseases is well known. Several studies have also revealed that similar therapeutic impacts of parent MSCs are also exhibited by MSCs-derived extracellular vesicles (EVs) including exosomes. In this review, we explored the therapeutic potential of both MSCs and exosomes in mitigating the COVID-19 induced cytokine storm as well as promoting the regeneration of alveolar tissue, attributed to the intrinsic cytokines and growth factor present in the secretome. The preliminary studies have demonstrated the safety and efficacy of MSCs and exosomes in mitigating symptoms associated with COVID-19. Thus, they can be used on compassionate basis, owing to their ability to endogenously repair and decrease the inflammatory reactions involved in the morbidity and mortality of COVID-19. However, more preclinical and clinical studies are warranted to understand their mechanism of action and further establish their safety and efficacy. Twit Text FOAVip Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective ????Hum Cell http://www.kidney.de/pget.php?&tw=1&pmid=32780299 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32780299 #FOAvip English Wikipedia <ref>{{Cite pmid|32780299}}</ref> Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective #MMPMID32780299 Gupta A; Kashte S; Gupta M; Rodriguez HC; Gautam SS; Kadam S Hum Cell 2020[Oct]; 33 (4): 907-918 PMID32780299show ga Acute respiratory distress syndrome (ARDS) is the main cause for the COVID-19 infection-related morbidity and mortality. Recent clinical evidences suggest increased level of cytokines and chemokines targeting lung tissue as a prominent etiological factor. The immunomodulatory effect of mesenchymal stem cells (MSCs) as the alternative therapy for the treatment of inflammatory and autoimmune diseases is well known. Several studies have also revealed that similar therapeutic impacts of parent MSCs are also exhibited by MSCs-derived extracellular vesicles (EVs) including exosomes. In this review, we explored the therapeutic potential of both MSCs and exosomes in mitigating the COVID-19 induced cytokine storm as well as promoting the regeneration of alveolar tissue, attributed to the intrinsic cytokines and growth factor present in the secretome. The preliminary studies have demonstrated the safety and efficacy of MSCs and exosomes in mitigating symptoms associated with COVID-19. Thus, they can be used on compassionate basis, owing to their ability to endogenously repair and decrease the inflammatory reactions involved in the morbidity and mortality of COVID-19. However, more preclinical and clinical studies are warranted to understand their mechanism of action and further establish their safety and efficacy. |*Exosomes[MESH] |*Mesenchymal Stem Cell Transplantation[MESH] |COVID-19[MESH] |Coronavirus Infections/etiology/immunology/mortality/*therapy[MESH] |Cytokines/metabolism[MESH] |Humans[MESH] |Inflammation Mediators/metabolism[MESH] |Lung/metabolism[MESH] |Mesenchymal Stem Cells/immunology[MESH] |Pandemics[MESH] |Pneumonia, Viral/etiology/immunology/mortality/*therapy[MESH]Mesenchymal stem cells and exosome therapy for COVID-19: current statu(epmc).pdf DeepDyve Pubget Overpricing